How to read: Every bubble is one Indian docetaxel exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Docetaxel report covers
KEY TAKEAWAYEvery figure in this report is grounded in real commercial docetaxel trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian docetaxel suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Docetaxel India trade report
P
Product scope
Docetaxel
All variants merged — branded and generic formulations of docetaxel
T
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
S
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
G
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
C
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
R
Shipments analysed
230
Every commercial docetaxel trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY2025-Q4 followed a mixed: Oct $654.2K, Nov $942.0K, Dec $638.2K. Shipment counts rose across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$654.2K
Oct USD
40 shipments
2
$942.0K
Nov USD
+44.0% MoM
3
$638.2K
Dec USD
-32.3% MoM
4
Mixed
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov rose 44.0% in USD but shipment count kept climbing.
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $654K, making it the middle month by value.
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: FRESENIUS KABI ONCOLOGY LTD maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import docetaxel from India, how much they buy, and who supplies each market
KEY TAKEAWAYUnited States absorbs 30.9% of India’s 2025-Q4 docetaxel trade ($691.5K). Beyond the top 10 destinations, 57 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Africa has 22 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 57 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much docetaxel India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$703K
31.5% of trade
18 countries · 77 shipments
Europe
$209K
9.4% of trade
4 countries · 24 shipments
Americas
$958K
42.9% of trade
13 countries · 47 shipments
Africa
$357K
16.0% of trade
22 countries · 74 shipments
Oceania
$7K
0.3% of trade
1 countries · 8 shipments
Fig 4.1 United States is the #1 corridor ($691K) — 30 flow arcs from India radiate across 5 continents.
How to read: The world map shows every country colored by how much Indian docetaxel it receives (light = low, dark = high). Orange arcs radiate from India to the top 30 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 10 bilateral trade lanes (India → destination) with top Indian suppliers
#
Destination
Total USD
Ships
#1 Indian supplier
USD
#2 Indian supplier
USD
#3 Indian supplier
USD
1
United States
$691K
4
MYLAN LABORATORIES LTD
$691K
—
—
—
—
2
South Korea
$214K
2
INTAS PHARMACEUTICALS LTD
$214K
—
—
—
—
3
Thailand
$141K
2
FRESENIUS KABI ONCOLOGY LTD
$141K
—
—
—
—
4
Colombia
$121K
2
FRESENIUS KABI ONCOLOGY LTD
$121K
—
—
—
—
5
Germany
$105K
5
FRESENIUS KABI ONCOLOGY LTD
$105K
—
—
—
—
6
Malaysia
$102K
3
FRESENIUS KABI ONCOLOGY LTD
$102K
—
—
—
—
7
Malta
$98K
12
EUGIA PHARMA SPECIALITIES LTD
$98K
—
—
—
—
8
Nepal
$88K
13
FRESENIUS KABI INDIA PVT LTD
$46K
ARISTO PHARMACEUTICALS PVT LTD
$36K
UNITED BIOTECH PVT LTD
$4K
9
Egypt
$85K
5
FRESENIUS KABI ONCOLOGY LTD
$85K
BIOZENTA LIFESCIENCE PVT LTD
$20
—
—
10
South Africa
$83K
5
INTAS PHARMACEUTICALS LTD
$56K
FRESENIUS KABI ONCOLOGY LTD
$27K
HEALTH BIOTECH LTD
$710
Table 4.1 — Top 10 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 31.5% of USD — but United States is the single largest market.
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
30.9%
#1 country share
United States alone
57.0%
Top 5 share
5 of 58 countries
86.1%
Top 15 share
Long tail of 43 countries = 13.9%
HHI 1252
Destination HHI
Competitive spread
58
Countries served
Global pharma reach from India
22
Africa countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
64 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAYMYLAN LABORATORIES LTD ($691.5K, 30.9% share) and FRESENIUS KABI ONCOLOGY LTD ($676.8K) together control 61.2% of India’s 2025-Q4 docetaxel trade. The top 5 suppliers hold 81.2%. 64 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian docetaxel suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 MYLAN LABORATORIES LTD leads by $15K over FRESENIUS KABI ONCOLOGY LTD — top 20 Indian exporters ranked by trade value
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: GETWELL PHARMA INDIA is #19 by value but #5 by volume.
Fig 5.2 FRESENIUS KABI ONCOLOGY LTD also leads by shipment count (39) but ranking shifts for volume-heavy players
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: GETWELL PHARMA INDIA moves from #5 by volume to #19 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 64 docetaxel suppliers split into strategic segments
KEY TAKEAWAY16 suppliers (25%) generate 94.4% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 MYLAN LABORATORIES LTD and FRESENIUS KABI ONCOLOGY LTD sit in the leaders zone — high volume AND high value.
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 94.4% of USD — classic concentration.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 5 destinations and up to 2 importers per destination.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 4 destinations and up to 4 importers per destination.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 2 destinations and up to 2 importers per destination.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 3 destinations and up to 1 importers per destination.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 3 destinations and up to 2 importers per destination.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 2 destinations and up to 2 importers per destination.
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
69 importers across 58 countries — who is buying Indian docetaxel and how much
KEY TAKEAWAYThe demand side is dramatically more fragmented than supply: the top 25 importers together hold only 75.9% of total USD. 96% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian docetaxel. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 MYLAN INSTITUTIONAL INC is the #1 importer at $691K (30.9%) — top 25 by trade value
How to read: Left semicircle = top 20 Indian suppliers; right = top 20 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian docetaxel prices vary by supplier, country and dosage form
KEY TAKEAWAYDocetaxel prices span 4756× ($0.044 → $209.24). The coefficient of variation is 1.95. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. EUGIA PHARMA SPECIALITIESSourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. MYLAN LABORATORIES LTDSourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. e.g. SAMEEKSHA PHARMACEUTICALS PVTSourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. e.g. ARECHAR HEALTHCARE LLPSourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAYExtreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 10 highest and 10 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
Date
Exporter
Country
Dosage
Qty
USD
$/unit
Why
Nov 2025
NU HOSPITALS PVT…
Maldives
Injection
8
$5K
$572.11
Sterile formulation premium
Oct 2025
CHOUDHARI IMPEX
Papua New Guinea
Injection
10
$2K
$209.81
Sterile formulation premium
Nov 2025
NARAYANA HRUDAYA…
Cayman Islands
Injection
2
$418.48
$209.24
Sterile formulation premium
Nov 2025
NARAYANA HRUDAYA…
Cayman Islands
Injection
2
$418.48
$209.24
Sterile formulation premium
Oct 2025
NARAYANA HRUDAYA…
Cayman Islands
Injection
1
$207.69
$207.69
Sterile formulation premium
Dec 2025
PIRZE LIFECARE P…
Equatorial Guinea
—
100
$12K
$119.72
Specialty / small-batch
Dec 2025
UNITED BIOTECH P…
Nepal
Injection
15
$1K
$93.50
Sterile formulation premium
Nov 2025
INTAS PHARMACEUT…
South Korea
—
2K
$171K
$91.63
Specialty / small-batch
Dec 2025
UNITED BIOTECH P…
Nepal
Injection
20
$1K
$60.53
Sterile formulation premium
Nov 2025
UNITED BIOTECH P…
Nepal
—
10
$602.45
$60.25
Specialty / small-batch
↓ TOP 10 LOWEST USD/UNIT
Date
Exporter
Country
Dosage
Qty
USD
$/unit
Why
Dec 2025
BIOZENTA LIFESCI…
Egypt
Injection
700
$19.69
$0.028
Sterile formulation premium
Dec 2025
ATLAS ENTERPRISES
Mexico
Injection
250
$9.99
$0.040
Sterile formulation premium
Dec 2025
M T MADON EXPORTS
Somalia
Injection
75
$3.30
$0.044
Sterile formulation premium
Dec 2025
BRUCK PHARMA PVT…
Cote d'Ivoire
Injection
4
$0.193
$0.048
Sterile formulation premium
Dec 2025
MBA PHARMACEUTIC…
Nigeria
Injection
100
$5.09
$0.051
Sterile formulation premium
Dec 2025
MBA PHARMACEUTIC…
Nigeria
Injection
200
$12.73
$0.064
Sterile formulation premium
Dec 2025
FRESENIUS KABI O…
Myanmar
Injection
1K
$103.93
$0.104
Sterile formulation premium
Dec 2025
FRESENIUS KABI O…
Philippines
Injection
2K
$168.89
$0.106
Sterile formulation premium
Dec 2025
KHANDELWAL LABOR…
Kenya
Injection
150
$16.28
$0.109
Sterile formulation premium
Dec 2025
SANSKRUTI PHARMA
Burkina Faso
Injection
100
$11.80
$0.118
Sterile formulation premium
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
Dosage form is the #1 price driver, not destination
Light cells = easy-entry markets for small suppliers
Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship docetaxel, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAYDocetaxel leaves India through 10+ ports. The top 5 (DELHI AIR, BANGALORE AIR, AHMEDABAD AIR) handle 91.5% of total USD. AIR moves 93% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 DELHI AIR handles $798K — top 10 Indian origin ports by trade value.
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
Route
Mode
Transit time
Notes
NHAVA SHEVA SEA (JNPT) → US East Coast
Sea
22–28 days
Via Suez; 2–3 transshipments typical
NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria)
Sea
18–24 days
Direct liner service available
MUMBAI AIR (SAHAR) → New York JFK
Air
3–5 days
Direct cargo; cold-chain available
MUNDRA SEA → Rotterdam
Sea
20–26 days
Via Suez; Hamburg also served
HYDERABAD AIR → London Heathrow
Air
2–4 days
Pharma-grade cargo corridor
CHENNAI SEA → Chittagong (Bangladesh)
Sea
7–12 days
Short-sea route; high frequency
RAXAUL → Birgunj (Nepal)
Road
1–2 days
Land border crossing
NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya)
Sea
14–20 days
Direct or via Colombo hub
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAYAIR dominates at 93% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
AIR
$2.1M
93.3% of USD · 93.0% of ships
ICD
$106K
4.7% of USD · 3.0% of ships
ROAD
$36K
1.6% of USD · 0.4% of ships
SEA
$9K
0.4% of USD · 3.5% of ships
Fig 8.3 The dominant corridor is BANGALORE AIR → Air → N. America ($693K).
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAYMalta is the most concentrated destination (HHI 10000, 1 suppliers). Kenya is the most competitive (HHI 2668).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 Malta (HHI 10,000) is the most concentrated — Kenya (HHI 2,668) is the most competitive.
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 20 of 20 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
Buyer
Country
Sole supplier
USD
Ships
Risk
MYLAN INSTITUTIONAL …
United States
MYLAN LABORATORI…
$691K
4
CRITICAL
FRESENIUS KABI (THAI…
Thailand
FRESENIUS KABI O…
$141K
2
HIGH
FRESENIUS KABI COLOM…
Colombia
FRESENIUS KABI O…
$121K
2
HIGH
FRESENIUS KABI DEUTS…
Germany
FRESENIUS KABI O…
$105K
5
HIGH
FRESENIUS KABI MALAY…
Malaysia
FRESENIUS KABI O…
$102K
3
HIGH
APL SWIFT SERVICES (…
Malta
EUGIA PHARMA SPE…
$98K
12
MEDIUM
IBNSINA PHARMA (S.A.…
Egypt
FRESENIUS KABI O…
$56K
2
MEDIUM
TO NABIL BANK LTD
Nepal
FRESENIUS KABI I…
$46K
4
MEDIUM
Conclusion: 66 buyers depend on exactly one Indian supplier, representing $1.8M in trade. 1 are rated CRITICAL — if their sole supplier fails, they have no backup. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
Buyer
Country
Suppliers
USD
Dominant
Resilience
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
Country
Tier
Lead
Price
Risk
Entry approach
United States
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
South Korea
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Thailand
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Colombia
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Germany
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
Malaysia
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Malta
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Nepal
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Egypt
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
South Africa
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Sri Lanka
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
DR Congo
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Ecuador
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Kenya
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Tanzania
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 12 in Fragile Dependency (concentrated + shrinking).
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 15 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAYQuick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 15 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
ID
Action
Timing
Impact
A1
Pitch top single-source buyer in United States
This Q
HIGH
A2
Offer alternative to top multi-source buyer
This Q
HIGH
A3
Audit Malta lock-ins (HHI 10000)
This Q
MED
A5
Enter DR Congo (3 suppliers)
This Q
HIGH
A6
Enter United States (1 suppliers)
This Q
MED
A8
Build South Korea distribution
6–12m
HIGH
A9
Bundle injection/infusion catalog for premium markets
6–12m
MED
B
FOR BUYERS
ID
Action
Timing
Impact
A4
Monitor rising exporters (climbers)
This Q
MED
A7
Register for United States tenders
6–12m
HIGH
A10
Track quarterly HHI shifts across key destinations
This Q
LOW
A11
Map competitor buyer portfolios quarterly
This Q
MED
A12
Qualify second source for single-source buyers
This Q
MED
§9.4 Easy-entry markets — 15 countries with ≤5 Indian suppliers
#
Country
Region
Suppliers
Q4 USD
Growth
Barrier
Why this is easy
1
DR Congo
Africa
3
$39K
+2279125.3%
LOW
Growing 2279125% with only 3 competitors
2
United States
Other
1
$691K
-100%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
3
Germany
Other
1
$105K
+136.4%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
4
South Korea
Asia
1
$214K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
5
Thailand
Asia
1
$141K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
6
Colombia
Other
1
$121K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
7
Malaysia
Asia
1
$102K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
8
Malta
Other
1
$98K
-100%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
9
Nepal
Asia
4
$88K
0%
LOW
Low competition (4 suppliers), accessible market
10
Egypt
Africa
2
$85K
0%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
11
South Africa
Africa
3
$83K
0%
LOW
Low competition (3 suppliers), accessible market
12
Sri Lanka
Asia
2
$52K
0%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
13
Ecuador
Other
2
$37K
+27.4%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
14
Tanzania
Africa
1
$33K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
15
United Arab Emirates
Other
2
$31K
0%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
This report covers 230 2025-Q4 Docetaxel shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/docetaxel
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAYThis section contains every one of the 230 2025-Q4 docetaxel shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian docetaxel shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
230
across all regions
TOTAL USD
$2.23M
2025-Q4 FOB value
UNITS
231.3K
tablets, capsules, etc.
SUPPLIERS
64
Indian exporters
BUYERS
69
global importers
COUNTRIES
58
destinations
§10.2 Regional breakdown
Africa
$357K
16.0%
22 ctry · 74 ships
Asia
$703K
31.5%
18 ctry · 77 ships
Europe
$209K
9.4%
4 ctry · 24 ships
Americas
$958K
42.9%
13 ctry · 47 ships
Oceania
$7K
0.3%
1 ctry · 8 ships
§10.3 Key insights from the data
🌍
Africa is the largest region at $357K (16.0%), spanning 22 countries.
🏢
64 Indian suppliers shipped to 69 buyers across 58 countries — average shipment value $10K.
📄
Top 0 markets: .
🔍
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
All 67 global docetaxel importers — complete list ranked by USD
KEY TAKEAWAYThis directory lists every company that imported Indian docetaxel in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
#
Buyer
Country
Ships
USD
Primary supplier
Dosage forms
1
MYLAN INSTITUTIONAL INC
United States
4
$691K
MYLAN LABORATORIES LTD
Injection
2
FRESENIUS KABI (THAILAND) LTD
Thailand
2
$141K
FRESENIUS KABI ONCOL…
Injection
3
FRESENIUS KABI COLOMBIA SAS
Colombia
2
$121K
FRESENIUS KABI ONCOL…
Injection
4
FRESENIUS KABI DEUTSCHLAND GMBH
Germany
5
$105K
FRESENIUS KABI ONCOL…
Injection
5
FRESENIUS KABI MALAYSIA SDN BHD
Malaysia
3
$102K
FRESENIUS KABI ONCOL…
Injection
6
APL SWIFT SERVICES (MALTA) LTD
Malta
12
$98K
EUGIA PHARMA SPECIAL…
solution for infusion
7
IBNSINA PHARMA (S.A.E.)
Egypt
2
$56K
FRESENIUS KABI ONCOL…
Injection
8
TO NABIL BANK LTD
Nepal
4
$46K
FRESENIUS KABI INDIA…
Injection
9
UNIQUE TRADE LINK PVT LTD
Nepal
1
$36K
ARISTO PHARMACEUTICA…
Injection
10
MEDICAL STORES DEPARTMENT
Tanzania
1
$33K
ARECHAR HEALTHCARE LLP
Injection
11
THE EGYPTIAN PHARMACEUTICAL TRADING
Egypt
2
$28K
FRESENIUS KABI ONCOL…
Injection
12
SUN PHARMACEUTICALS MOROCCO LL
Morocco
1
$28K
SUN PHARMACEUTICAL I…
Injection
13
FRESENIUS KABI SOUTH AFRICA (PTY) L
South Africa
3
$27K
FRESENIUS KABI ONCOL…
Injection
14
PEOPLE S BANK
Sri Lanka
1
$22K
UNITED BIOTECH PVT LTD
Injection
15
PEOPLES BANK
Sri Lanka
1
$22K
UNITED BIOTECH PVT LTD
Injection
16
FRESENIUS KABI S.A
Ecuador
2
$20K
FRESENIUS KABI ONCOL…
Injection
17
CORPORACION FARMACEUTICA DE C.A.S.A
Nicaragua
1
$16K
UNITED BIOTECH PVT LTD
Injection
18
ATCO PHARMA INTERNATIONAL PVT LTD
Pakistan
2
$15K
FRESENIUS KABI ONCOL…
Injection
19
FOR THE ORDER OF
United Arab Emirates
7
$15K
3S CORP
Injection
20
FRESENIUS KABI MEXICO, S.A. DE C.V
Mexico
1
$14K
FRESENIUS KABI ONCOL…
Injection
21
ALEMBIC PHARMACEUTICALS SPA
Chile
2
$13K
ALEMBIC PHARMACEUTIC…
Injection
22
LAQFAGAL FARMA INDUSTRIA SRL
Bolivia
1
$13K
HUMBLE HEALTHCAARE LTD
Injection
23
CENTRAIMED
Equatorial Guinea
1
$12K
PIRZE LIFECARE PVT LTD
24
W H O
Afghanistan
1
$11K
VENUS REMEDIES LTD
Injection
25
FRESENIUS KABI CHILE LTDA
Chile
1
$10K
FRESENIUS KABI ONCOL…
Injection
26
SALAMA PHARMACEUTICALS LTD
Kenya
1
$8K
UNITED BIOTECH PVT LTD
Injection
27
SEASONS PHARMACEUTICALS PVT LTD
Zimbabwe
1
$8K
NAPROD LIFE SCIENCES…
Injection
28
MENNA PHARMACEUTICALS IMPORT PLC
Ethiopia
1
$8K
BETA DRUGS LTD
concentrate
29
P C P L
Zimbabwe
1
$7K
VENUS REMEDIES LTD
Injection
30
FRESENIUS KABI TAIWAN LTD
Taiwan
1
$7K
FRESENIUS KABI ONCOL…
Injection
31
FRESENIUS KABI PHILIPPINES INC
Philippines
2
$5K
FRESENIUS KABI ONCOL…
Injection
32
INDIRA GANDHI MEMOROAL HOSPITAL
Maldives
1
$5K
NU HOSPITALS PVT LTD
Injection
33
EUROFINS BIOPHARMA PRODUCT TESTING
Hungary
3
$4K
FRESENIUS KABI ONCOL…
Injection
34
NIKHIL PHARMA PVT LTD
Nepal
5
$4K
UNITED BIOTECH PVT LTD
concentrate, Injection
35
LOTUS PHARMA
Burundi
5
$4K
KHANDELWAL LABORATOR…
Injection, Solution
36
COMMERCIAL BANK OF ETHIOPIA
Ethiopia
1
$4K
NEON LABORATORIES LTD
Injection
37
NAIROBI ENTERPRISES LTD
Kenya
1
$3K
GETWELL PHARMA INDIA…
Injection
38
NOVO GENERAL TRADING FZE
United Arab Emirates
2
$2K
DOSSMEGT PHARMACEUTI…
combipack
39
TRADE SERVICES DFCC BANK PLC
Sri Lanka
2
$2K
UNITED BIOTECH PVT LTD
Injection
40
THE ESSES PHARMACY (PRIVATE)LTD
Sri Lanka
2
$2K
GETWELL PHARMA INDIA…
Injection
41
FOR .THE ORDER OF
Kenya
4
$2K
3S CORP
Injection
42
RADEEP SERVICES
Singapore
3
$2K
PHARMA CHOICE LLP
Tablet
43
HEALTH CITY CAYMAN ISLANDS (HCCI)
Cayman Islands
9
$2K
NARAYANA HRUDAYALAYA…
Injection
44
BISTRA PHARMA LINK PVT LTD
Nepal
2
$2K
KHANDELWAL LABORATOR…
Injection
45
THE ESSES PHARMACY (PRIVATE)
Sri Lanka
1
$2K
GETWELL PHARMA INDIA…
concentrate
46
EHSAN COMERCIO GERAL LDA
Angola
1
$1K
HAMD OVERSEAS
Injection
47
LLC TIBBI JAHON
Tajikistan
1
$1K
M.K.PHARMA
Vial
48
ASHRO MYANMAR LTD
Myanmar
1
$1K
VEXXA LIFESCIENCES P…
Injection
49
QUALIMETRIX SA
Greece
3
$1K
VENUS REMEDIES LTD
Solution
50
GULF IMPEX FZC
Afghanistan
2
$1K
MEDMATRIX ASSOCIATES
Injection
51
DALIAN CHAOHONGSUPPLY CHAIN MANAGEM
China
1
$1K
JMB PHARMACEUTICALS …
Injection
52
RGCO (PTY) LTD
South Africa
1
$709.79
HEALTH BIOTECH LTD
Injection
53
HOPITAL CARAMED-CLINIQUE DU CANCER
Haiti
1
$682.23
DOSSMEGT PHARMACEUTI…
Injection
54
HPITAL CARAMEDCLINIQUE DU CANCER
Haiti
2
$681.45
DOSSMEGT PHARMACEUTI…
Injection
55
IBL LTD
Mauritius
1
$528.31
HUMANIQE BIOPHARMACE…
Injection
56
CENTRALE D ACHATS DE MEDICAMENTS ES
Madagascar
1
$493.71
ZUVIUS LIFESCIENCES …
Injection
57
FRESENIUS KABI (SINGAPORE) PTE LTD
Singapore
3
$466.28
FRESENIUS KABI ONCOL…
Injection
58
IMPORT INNOVATORS VENTURES INC
Philippines
1
$430.29
PHARMA CHOICE LLP
Injection
59
ABU AHMED
Kenya
2
$347.94
AMARI TRADE ALLIANCE…
Injection
60
FRESENIUS KABI MEXICO S.A. DE C.V
Mexico
1
$240.55
FRESENIUS KABI ONCOL…
Injection
61
LATOYA SHONELL GOODINGS
Guyana
1
$198.89
PHARMACO LIFESCIENCES
Injection
62
OUMAR KONE
Mali
1
$156.76
KHATU ENTERPRISES
Injection
63
IMPERIAL PHOENIX CO LTD
Myanmar
1
$103.93
FRESENIUS KABI ONCOL…
Injection
64
PSM PHARMACEUTICALS LTD
Kenya
2
$37.44
KHANDELWAL LABORATOR…
Injection
65
DISTRIBUIDORA MEDICA PAREDES S.DE R
Mexico
1
$9.99
ATLAS ENTERPRISES
Injection
66
MOHAMED AHEMED MOHAMUD
Somalia
1
$3.30
M T MADON EXPORTS
Injection
67
HANITRA RAZAOARIMANANA
Madagascar
1
$1.04
GETWELL PHARMA INDIA…
Injection
This report covers 230 2025-Q4 Docetaxel shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/docetaxel
Talk to our trade analyst
Need a custom docetaxel report or a deeper dive into any market? Our team is ready.